Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

360 ARTÍCULOS , VIENDO DEL 181 AL 195

[Prescription differences of dementia drugs in urban and rural areas in Germany]

Bohlken J, Selke GW, van den Bussche H.

Psychiatr Prax. 2011 Jul;38(5):232-6. doi: 10.1055/s-0030-1266020. Epub 2011 Mar 21.

Ginseng

Barton D.

Oncology (Williston Park). 2011 Apr;25(4 Suppl Nurse Ed):42-5.

Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients

Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L.

Alzheimers Dement. 2011 May;7(3):318-27. doi: 10.1016/j.jalz.2010.09.001.

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.

Expert Opin Ther Targets. 2011 Oct;15(10):1153-62. doi: 10.1517/14728222.2011.600691. Epub 2011 Jul 12.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab

Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, Siemers E, Barakos J.

Alzheimers Dement. 2011 Jul;7(4):396-401. doi: 10.1016/j.jalz.2011.05.2353.

Does hospice improve quality of care for persons dying from dementia?

Teno JM, Gozalo PL, Lee IC, Kuo S, Spence C, Connor SR, Casarett DJ.

J Am Geriatr Soc. 2011 Aug;59(8):1531-6. doi: 10.1111/j.1532-5415.2011.03505.x. Epub 2011 Jul 28.

Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings

Reese JP, Hessmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J, Baum E, Dannhoff F, Müller MJ, Jessen F, Geldsetzer MB, Dodel R.

J Alzheimers Dis. 2011;27(4):723-36. doi: 10.3233/JAD-2011-110539.

Co-morbidity and drug treatment in Alzheimer's disease. A cross sectional study of participants in the dementia study in northern Norway

Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA.

BMC Geriatr. 2011 Oct 4;11:58. doi: 10.1186/1471-2318-11-58.

Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment

Molinuevo JL, Berthier ML, Rami L.

Arch Gerontol Geriatr. 2011 Jan-Feb;52(1):18-22. doi: 10.1016/j.archger.2009.11.004. Epub 2009 Nov 30.

Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease

Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J.

Int J Geriatr Psychiatry. 2011 Feb;26(2):150-7. doi: 10.1002/gps.2507.

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?

Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; DIADS-2 Research Group.

Int J Geriatr Psychiatry. 2011 Jun;26(6):573-83. doi: 10.1002/gps.2565.

Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients

Keller C, Kadir A, Forsberg A, Porras O, Nordberg A.

J Alzheimers Dis. 2011;24(1):109-23. doi: 10.3233/JAD-2010-101290.

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population

Van Puyvelde K, Mets T; RODOS Study Group.

Geriatr Gerontol Int. 2011 Jul;11(3):256-61. doi: 10.1111/j.1447-0594.2010.00674.x. Epub 2011 Jan 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias